Recursion Pharmaceuticals, founded in 2013 and headquartered in Salt Lake City, Utah, is a clinical-stage biotechnology company that combines artificial intelligence, automation, and experimental biology to industrialize drug discovery. Their proprietary platform, the Recursion Operating System (OS), enables the mapping and navigation of trillions of biological and chemical relationships, facilitating the rapid identification of potential therapeutic candidates. Recursion's diverse pipeline includes treatments for rare genetic diseases and various cancers. The company has established significant partnerships with industry leaders such as Bayer, Roche, and Genentech to advance innovative therapies. In August 2024, Recursion expanded its capabilities by acquiring Exscientia, a UK-based biotechnology firm specializing in AI-driven drug discovery, for $688 million. This strategic move underscores Recursion's commitment to leveraging cutting-edge technology to decode biology and accelerate the development of life-changing medicines.